Opinion: Independent third-party entities as a model for validation of commercial antibodies
Carl Laflamme, A.M. Edwards, Anita Bandrowski, Peter S. McPherson
Topics & Concepts
IncentivePublic domainComputer scienceProfit (economics)Domain (mathematical analysis)AntibodyPublic opinionBusinessData sciencePolitical scienceEconomicsMedicineImmunologyMicroeconomicsMathematicsMathematical analysisTheologyPhilosophyLawPoliticsMonoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical MethodsViral Infectious Diseases and Gene Expression in Insects